Zentalis Pharmaceuticals (ZNTL) Stock Price, Quote, News & History | Benzinga

Zentalis Pharmaceuticals Inc (ZNTL) Stock Price, Quote, News & History

ZNTLNASDAQ

Trade with Public

Trade with Public

$3.68

-0.025-0.67%

At close: Aug 18, 5:00 PM EST

$3.63

-0.05-1.36%

After Hours: 5:43 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.75

Close

$3.68

Volume / Avg.

1.20M / 1.21M

Day Range

$3.58 - $3.86

52 Wk Range

1.21 - 6.95

Market Cap

$343.66M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

36

Short Interest

6.94%

Days to Cover

4.16

Recent Zentalis Pharmaceuticals Inc News

ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday

US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.

Avi Kapoor

Nasdaq Moves Higher; US Inflation Rate Accelerates In March

U.S. stocks mixed, Nasdaq up 100 points. Inflation rate surges to 3.3%. Japan's Nikkei 225 and China's Shanghai Composite close higher.

Avi Kapoor

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.

Alex Perry

Organon, CoreWeave, WhiteFiber And Other Big Stocks Moving Higher On Friday

Dow Jones fell 100 points as Sun Pharma offered 12 billion to buy Organon, Organon shares jumped 26.4%, other stocks also rose.

Avi Kapoor

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies. Zentalis plans to work with trial investigators to continue development while presenting additional data later this year.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-128.10M

Investing Cash Flow (TTM)

120.81M

Financing Cash Flow (TTM)

-5.53M

Free Cash Flow (TTM)

-128.13M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-12.82M

Analyst Trends and Forecast

1

Mar

1

Apr

2

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$209.24M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

2.44

Earnings Yield % (TTM)

-52.97%

Earnings Yield % (FWD)

-63.24%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.52

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$24.78M

Debt to Equity

0.23

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.75

Close

$3.68

Volume / Avg.

1.20M / 1.21M

Day Range

$3.58 - $3.86

52 Wk Range

1.21 - 6.95

Market Cap

$343.66M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

36

Short Interest

6.94%

Days to Cover

4.16

About

Sector

Health Care

Industry

Biotechnology

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Zentalis Pharmaceuticals (ZNTL) stock?

A

You can purchase shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Zentalis Pharmaceuticals (ZNTL) competitors?

A

Other companies in Zentalis Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Zentalis Pharmaceuticals (ZNTL) stock?

A

Zentalis Pharmaceuticals has a consensus price target of $8.56.

Q

What is the current price for Zentalis Pharmaceuticals (ZNTL)?

A

The stock price for Zentalis Pharmaceuticals (NASDAQ: ZNTL) is $3.63 last updated August 18, 2026 at 5:43 PM EDT.

Q

Does Zentalis Pharmaceuticals (ZNTL) pay a dividend?

A

There are no upcoming dividends for Zentalis Pharmaceuticals.

Q

When is Zentalis Pharmaceuticals (NASDAQ:ZNTL) reporting earnings?

A

Zentalis Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Zentalis Pharmaceuticals (ZNTL) going to split?

A

There is no upcoming split for Zentalis Pharmaceuticals.

Q

What sector and industry does Zentalis Pharmaceuticals (ZNTL) operate in?

A

Zentalis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.